Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.

Clin Cancer Res. 2018 Sep 12. pii: clincanres.1943.2018. doi: 10.1158/1078-0432.CCR-18-1943. [Epub ahead of print]

PMID:
30209161
2.

Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Population-Based Study.

Vos M, Ho VKY, Oosten AW, Verhoef C, Sleijfer S.

Oncologist. 2018 Sep 6. pii: theoncologist.2017-0383. doi: 10.1634/theoncologist.2017-0383. [Epub ahead of print]

PMID:
30190301
3.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 Sep 5. doi: 10.1093/annonc/mdy320. [Epub ahead of print] No abstract available.

PMID:
30188977
4.

89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up.

Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, de Vries EGE, Schröder CP.

Eur J Nucl Med Mol Imaging. 2018 Jul 30. doi: 10.1007/s00259-018-4099-8. [Epub ahead of print]

PMID:
30058029
5.

Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study.

Timbergen MJM, van de Poll-Franse LV, Grünhagen DJ, van der Graaf WT, Sleijfer S, Verhoef C, Husson O.

Qual Life Res. 2018 Jul 16. doi: 10.1007/s11136-018-1931-3. [Epub ahead of print]

PMID:
30014458
6.

Prognostic value of intra-tumoral CD8+ /FoxP3+ lymphocyte ratio in patients with resected colorectal cancer liver metastasis.

Sideras K, Galjart B, Vasaturo A, Pedroza-Gonzalez A, Biermann K, Mancham S, Nigg AL, Hansen BE, Stoop HA, Zhou G, Verhoef C, Sleijfer S, Sprengers D, Kwekkeboom J, Bruno MJ.

J Surg Oncol. 2018 Jul;118(1):68-76. doi: 10.1002/jso.25091. Epub 2018 Jun 7.

PMID:
29878369
7.

Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkovski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 May 28. doi: 10.1093/annonc/mdy095. [Epub ahead of print] No abstract available.

PMID:
29846513
8.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkovski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN.

Ann Oncol. 2018 May 28. doi: 10.1093/annonc/mdy096. [Epub ahead of print] No abstract available.

PMID:
29846498
9.

Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA.

Weerts MJA, Timmermans EC, van de Stolpe A, Vossen RHAM, Anvar SY, Foekens JA, Sleijfer S, Martens JWM.

Neoplasia. 2018 Jul;20(7):687-696. doi: 10.1016/j.neo.2018.05.003. Epub 2018 May 26.

10.

Evidence on the cost of breast cancer drugs is required for rational decision making.

Berghuis AMS, Koffijberg H, Terstappen LWMM, Sleijfer S, IJzerman MJ.

Ecancermedicalscience. 2018 Apr 16;12:825. doi: 10.3332/ecancer.2018.825. eCollection 2018.

11.

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.

de Kruijff IE, Timmermans AM, den Bakker MA, Trapman-Jansen AMAC, Foekens R, Meijer-Van Gelder ME, Oomen-de Hoop E, Smid M, Hollestelle A, van Deurzen CHM, Foekens JA, Martens JWM, Sleijfer S.

Cancers (Basel). 2018 May 5;10(5). pii: E134. doi: 10.3390/cancers10050134.

12.

Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients.

Nanou A, Coumans FAW, van Dalum G, Zeune LL, Dolling D, Onstenk W, Crespo M, Fontes MS, Rescigno P, Fowler G, Flohr P, Brune C, Sleijfer S, de Bono JS, Terstappen LWMM.

Oncotarget. 2018 Apr 10;9(27):19283-19293. doi: 10.18632/oncotarget.25019. eCollection 2018 Apr 10.

13.

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.

Bins S, Basak EA, El Bouazzaoui S, Koolen SLW, Oomen-de Hoop E, van der Leest CH, van der Veldt AAM, Sleijfer S, Debets R, van Schaik RHN, Aerts JGJV, Mathijssen RHJ.

Br J Cancer. 2018 May;118(10):1296-1301. doi: 10.1038/s41416-018-0074-1. Epub 2018 Apr 26.

PMID:
29695768
14.

Differences in recurrence and survival of extremity liposarcoma subtypes.

Vos M, Koseła-Paterczyk H, Rutkowski P, van Leenders GJLH, Normantowicz M, Lecyk A, Sleijfer S, Verhoef C, Grünhagen DJ.

Eur J Surg Oncol. 2018 Sep;44(9):1391-1397. doi: 10.1016/j.ejso.2018.03.028. Epub 2018 Apr 6.

PMID:
29673808
15.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
16.

European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.

Touati N, Schöffski P, Litière S, Judson I, Sleijfer S, van der Graaf WT, Italiano A, Isambert N, Gil T, Blay JY, Stark D, Brodowicz T, Marréaud S, Gronchi A.

Clin Oncol (R Coll Radiol). 2018 Jul;30(7):448-454. doi: 10.1016/j.clon.2018.02.065. Epub 2018 Mar 15.

PMID:
29550245
17.

Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.

Sleijfer S, Rizzo E, Litière S, Mathijssen RHJ, Judson IR, Gelderblom H, Van Der Graaf WTA, Gronchi A.

Acta Oncol. 2018 Aug;57(8):1117-1126. doi: 10.1080/0284186X.2018.1449248. Epub 2018 Mar 9.

PMID:
29521151
18.

Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.

van IJzendoorn DGP, Sleijfer S, Gelderblom H, Eskens FALM, van Leenders GJLH, Szuhai K, Bovée JVMG.

Clin Cancer Res. 2018 Jun 1;24(11):2678-2687. doi: 10.1158/1078-0432.CCR-17-3512. Epub 2018 Mar 6.

PMID:
29511030
19.

An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells.

Sieuwerts AM, Mostert B, van der Vlugt-Daane M, Kraan J, Beaufort CM, Van M, Prager WJC, De Laere B, Beije N, Hamberg P, Westgeest HM, Tascilar M, Dirix LY, Onstenk W, de Wit R, Lolkema MP, Mathijssen RHJ, Martens JWM, Sleijfer S.

J Mol Diagn. 2018 May;20(3):316-325. doi: 10.1016/j.jmoldx.2018.01.008. Epub 2018 Feb 21.

PMID:
29474983
20.

Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, Van Kerckhove P, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff I, van Dam V, Brouwer A, van Dam PJ, Van den Eynden G, Rutten A, Sleijfer S, Vandebroek J, Van Laere S, Dirix L.

Prostate. 2018 May;78(6):435-445. doi: 10.1002/pros.23488. Epub 2018 Feb 12.

PMID:
29431193
21.

Sensitive detection of mitochondrial DNA variants for analysis of mitochondrial DNA-enriched extracts from frozen tumor tissue.

Weerts MJA, Timmermans EC, Vossen RHAM, van Strijp D, Van den Hout-van Vroonhoven MCGN, van IJcken WFJ, van der Zaag PJ, Anvar SY, Sleijfer S, Martens JWM.

Sci Rep. 2018 Feb 2;8(1):2261. doi: 10.1038/s41598-018-20623-7.

22.

Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out.

van de Wetering RAW, Sleijfer S, Feldman DR, Funt SA, Bosl GJ, de Wit R.

J Clin Oncol. 2018 Mar 20;36(9):837-840. doi: 10.1200/JCO.2017.76.5610. Epub 2018 Feb 1. No abstract available.

PMID:
29389229
23.

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).

Lindner LH, Litière S, Sleijfer S, Benson C, Italiano A, Kasper B, Messiou C, Gelderblom H, Wardelmann E, Le Cesne A, Blay JY, Marreaud S, Hindi N, Desar IME, Gronchi A, van der Graaf WTA.

Int J Cancer. 2018 Jun 15;142(12):2610-2620. doi: 10.1002/ijc.31286. Epub 2018 Feb 14.

24.

Severe sarcopenia might be associated with a decline of physical independence in older patients undergoing chemotherapeutic treatment.

Rier HN, Jager A, Meinardi MC, van Rosmalen J, Kock MCJM, Westerweel PE, Trajkovic M, Sleijfer S, Levin MD.

Support Care Cancer. 2018 Jun;26(6):1781-1789. doi: 10.1007/s00520-017-4018-8. Epub 2017 Dec 15.

PMID:
29247308
25.

EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives.

Vos M, Sleijfer S.

Eur J Cancer. 2018 Jan;88:87-91. doi: 10.1016/j.ejca.2017.10.020. Epub 2017 Dec 1. Review.

PMID:
29202389
26.

Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey.

Rothermundt C, Fischer GF, Bauer S, Blay JY, Grünwald V, Italiano A, Kasper B, Kollár A, Lindner LH, Miah A, Sleijfer S, Stacchiotti S, Putora PM.

Oncologist. 2018 Apr;23(4):461-467. doi: 10.1634/theoncologist.2017-0391. Epub 2017 Nov 30. Review.

PMID:
29192019
27.

Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer.

Rier HN, Jager A, Sleijfer S, van Rosmalen J, Kock MCJM, Levin MD.

Breast Cancer Res Treat. 2018 Feb;168(1):95-105. doi: 10.1007/s10549-017-4574-0. Epub 2017 Nov 17.

PMID:
29147870
28.

Breast cancer genomics and immuno-oncological markers to guide immune therapies.

Hammerl D, Smid M, Timmermans AM, Sleijfer S, Martens JWM, Debets R.

Semin Cancer Biol. 2018 Oct;52(Pt 2):178-188. doi: 10.1016/j.semcancer.2017.11.003. Epub 2017 Nov 6. Review.

29.

Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.

Beije N, Sieuwerts AM, Kraan J, Van NM, Onstenk W, Vitale SR, van der Vlugt-Daane M, Dirix LY, Brouwer A, Hamberg P, de Jongh FE, Jager A, Seynaeve CM, Jansen MPHM, Foekens JA, Martens JWM, Sleijfer S.

Mol Oncol. 2018 Jan;12(1):48-57. doi: 10.1002/1878-0261.12147. Epub 2017 Nov 17.

30.

Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.

Verboom MC, Kloth JSL, Swen JJ, van der Straaten T, Bovée JVMG, Sleijfer S, Reyners AKL, Mathijssen RHJ, Guchelaar HJ, Steeghs N, Gelderblom H.

Eur J Cancer. 2017 Nov;86:226-232. doi: 10.1016/j.ejca.2017.09.025. Epub 2017 Oct 18.

PMID:
29054076
31.

Molecular Tumor Boards: current practice and future needs.

van der Velden DL, van Herpen CML, van Laarhoven HWM, Smit EF, Groen HJM, Willems SM, Nederlof PM, Langenberg MHG, Cuppen E, Sleijfer S, Steeghs N, Voest EE.

Ann Oncol. 2017 Dec 1;28(12):3070-3075. doi: 10.1093/annonc/mdx528.

PMID:
29045504
32.

Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.

Beije N, Helmijr JC, Weerts MJA, Beaufort CM, Wiggin M, Marziali A, Verhoef C, Sleijfer S, Jansen MPHM, Martens JWM.

Mol Oncol. 2016 Dec;10(10):1575-1584. doi: 10.1016/j.molonc.2016.10.001.

33.

Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma.

de Groot S, Redekop WK, Versteegh MM, Sleijfer S, Oosterwijk E, Kiemeney LALM, Uyl-de Groot CA.

Qual Life Res. 2018 Jan;27(1):115-124. doi: 10.1007/s11136-017-1704-4. Epub 2017 Sep 15.

34.

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Weeber F, Cirkel GA, Hoogstraat M, Bins S, Gadellaa-van Hooijdonk CGM, Ooft S, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Besselink NJM, Horlings HM, Steeghs N, de Jonge MJ, Langenberg MHG, Wessels LFA, Cuppen EPJG, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Oncotarget. 2017 Mar 8;8(33):55582-55592. doi: 10.18632/oncotarget.16029. eCollection 2017 Aug 15.

35.

Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.

Amirnasr A, Verdijk RM, van Kuijk PF, Taal W, Sleijfer S, Wiemer EAC.

PLoS One. 2017 Aug 15;12(8):e0183155. doi: 10.1371/journal.pone.0183155. eCollection 2017.

36.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.

37.

Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.

Beije N, Kraan J, den Bakker MA, Maat APWM, van der Leest C, Cornelissen R, Van NM, Martens JWM, Aerts JGJV, Sleijfer S.

Cell Oncol (Dordr). 2017 Oct;40(5):511-519. doi: 10.1007/s13402-017-0327-7. Epub 2017 Jun 2.

38.

First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.

Rier HN, Levin MD, van Rosmalen J, Bos MMEM, Drooger JC, de Jong P, Portielje JEA, Elsten EMP, Ten Tije AJ, Sleijfer S, Jager A.

Oncologist. 2017 Aug;22(8):901-909. doi: 10.1634/theoncologist.2016-0448. Epub 2017 May 22.

39.

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.

De Groot S, Blommestein HM, Redekop WK, Sleijfer S, Kiemeney LALM, Oosterwijk E, Uyl-de Groot CA.

PLoS One. 2017 May 22;12(5):e0177364. doi: 10.1371/journal.pone.0177364. eCollection 2017.

40.

Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA.

Weerts MJA, van Marion R, Helmijr JCA, Beaufort CM, Krol NMG, Trapman-Jansen AMAC, Dinjens WNM, Sleijfer S, Jansen MPHM, Martens JWM.

Sci Rep. 2017 May 18;7(1):2136. doi: 10.1038/s41598-017-02388-7.

41.

Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer.

Sideras K, Biermann K, Yap K, Mancham S, Boor PPC, Hansen BE, Stoop HJA, Peppelenbosch MP, van Eijck CH, Sleijfer S, Kwekkeboom J, Bruno MJ.

Int J Cancer. 2017 Aug 1;141(3):572-582. doi: 10.1002/ijc.30760. Epub 2017 May 19.

42.

Low Tumor Mitochondrial DNA Content Is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy.

Weerts MJA, Hollestelle A, Sieuwerts AM, Foekens JA, Sleijfer S, Martens JWM.

Clin Cancer Res. 2017 Aug 15;23(16):4735-4743. doi: 10.1158/1078-0432.CCR-17-0032. Epub 2017 Apr 18.

43.

Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.

Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schöffski P, Leyvraz S, Italiano A, Grünwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litière S, Marreaud S, van der Graaf W, Gronchi A, Verweij J; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group.

J Clin Oncol. 2017 May 20;35(15):1713-1720. doi: 10.1200/JCO.2016.71.0228. Epub 2017 Mar 31.

PMID:
28362562
44.

PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.

Sideras K, Biermann K, Verheij J, Takkenberg BR, Mancham S, Hansen BE, Schutz HM, de Man RA, Sprengers D, Buschow SI, Verseput MC, Boor PP, Pan Q, van Gulik TM, Terkivatan T, Ijzermans JN, Beuers UH, Sleijfer S, Bruno MJ, Kwekkeboom J.

Oncoimmunology. 2017 Jan 3;6(2):e1273309. doi: 10.1080/2162402X.2016.1273309. eCollection 2017.

45.

Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.

Wiemer EAC, Wozniak A, Burger H, Smid M, Floris G, Nzokirantevye A, Sciot R, Sleijfer S, Schöffski P.

Eur J Cancer. 2017 Apr;75:33-40. doi: 10.1016/j.ejca.2016.12.018. Epub 2017 Feb 16.

PMID:
28214655
46.

Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions.

van Dessel LF, Beije N, Helmijr JC, Vitale SR, Kraan J, Look MP, de Wit R, Sleijfer S, Jansen MP, Martens JW, Lolkema MP.

Mol Oncol. 2017 Mar;11(3):295-304. doi: 10.1002/1878-0261.12037. Epub 2017 Feb 22.

47.

Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study.

Verboom MC, Ouwerkerk J, Steeghs N, Lutjeboer J, Martijn Kerst J, van der Graaf WTA, Reyners AKL, Sleijfer S, Gelderblom H.

Clin Sarcoma Res. 2017 Jan 31;7:2. doi: 10.1186/s13569-017-0066-6. eCollection 2017.

48.

Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib.

Kloth JSL, Verboom MC, Swen JJ, van der Straaten T, Sleijfer S, Reyners AKL, Steeghs N, Gelderblom H, Guchelaar HJ, Mathijssen RHJ.

Pharmacogenomics J. 2018 Jan;18(1):49-55. doi: 10.1038/tpj.2016.83. Epub 2017 Jan 24.

PMID:
28117434
49.

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients.

Klaver Y, van Steenbergen SC, Sleijfer S, Debets R, Lamers CH.

Front Immunol. 2016 Dec 26;7:648. doi: 10.3389/fimmu.2016.00648. eCollection 2016.

50.

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.

Cirkel GA, Hamberg P, Sleijfer S, Loosveld OJL, Dercksen MW, Los M, Polee MB, van den Berkmortel F, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JEA, Peters FPJ, Klümpen HJ, van der Noort V, Haanen JBAG, Voest EE; Dutch WIN-O Consortium.

JAMA Oncol. 2017 Apr 1;3(4):501-508. doi: 10.1001/jamaoncol.2016.5202.

PMID:
27918762

Supplemental Content

Loading ...
Support Center